Orchestra BioMed Holdings Inc

Rule 10b5-1 Trading Arrangements

During the three months ended December 31, 2023, no director or officer (as defined in Rule 16a-1(f) of the Exchange Act) informed us of theadoption ortermination a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(c) of Regulation S-K.

Director Appointment

On March 26, 2024, the Board elected Mr. David Pacitti to serve as a Class II director, effective immediately. Mr. Pacitti will fill the vacancy created by Mr. Geoffrey Smith’s resignation as a Class II director of the Board. Mr. Pacitti was also appointed to serve as a member of each of the Company’s Audit Committee and Compensation Committee on March 26, 2024.

For a description of Mr. Pacitti’s business experience, please see the information under the heading “Non-Executive Directors—David Pacitti” in Item 10 of this Annual Report on Form 10-K.

The selection of Mr. Pacitti to serve as a director of the Company was not pursuant to any arrangement or understanding with any other person. There are no family relationships between Mr. Pacitti and any director or executive officer of the Company, and there are no transactions between Mr. Pacitti and the Company that would be required to be reported under Item 404(a) of Regulation S-K.

For his service as a director, Mr. Pacitti will be entitled to receive the compensation for non-employee directors described under the heading “Director Compensation Policy” in Item 11 of this Annual Report on Form 10-K. Mr. Pacitti has also entered into our standard form indemnification agreement, the form of which was filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on January 31, 2023.